reliance on a functional immune system, gives this agent certain advantages over the other radiopharmaceuticals.
In respiratory infection imaging, an important advancement would be the ability to quantitatively delineate lung inflammation, allowing one to monitor the therapeutic response in a variety of conditions. Current studies suggest PET should be considered the most accurate quantitative method.
Scintigraphy has much to offer in localizing abdominal infection as well as Tc-ciprofloxacin SPECT was reported to be >80% sensitive in patients more than 6 months post-surgery. FDG PET has also been suggested for this purpose and may play a larger role than originally thought.
It appears PET/CT is gaining support, especially in imaging those with fever of unknown origin or nonfunctional immune systems. While an infection specific agent is lacking, the development of one would greatly advance our ability to detect, localize, and quantify infections. Overall, imaging such an agent via SPECT/CT or PET/CT will pave the way for greater clinical reliability in the localization of infection.
The Development of Infection Specific Imaging Agents
Since the advent of 67 Ga citrate for routine infection imaging, a variety of agents have been developed and evaluated to better localize and detect areas of infection within the body. There has certainly been some advancement since the introduction of 67 Ga citrate in 1971, but a true infection-specific imaging agent has yet to be developed.
Almost all of the commonly used imaging agents localize to areas of inflammation rather than specifically those of infection, which makes clinical interpretation difficult and at times unreliable, particularly when the infection requires aggressive therapeutic intervention.
Inflammation and infection are different processes. Inflammation is merely a nonspecific immune response -one which does not require the presence of microorganisms to occur. Inflammation can occur from trauma, ischemia, neoplasm, autoimmune attack, or invasion by micro-organisms. Conversely, the presence of a locus of micro-organisms may not lead to inflammation in the immunocompromised patient, but still constitutes a site of infection. It should be recognized that all radiopharmaceuticals accumulate to some extent in this quality due to inflammation at the site of infection (1, 2) .
Granulocytes play an important role in the pathophysiology of infections and the development of imaging agents concerning infections. There are 3 physiological compartments that are involved in the granulocyte kinetics: the circulating and marginating granulocytes which constitute the total blood pool, the granulocyte pool in the bone marrow responsible for the development and release of granulocytes and the pools within which the blood granulocytes are physiologically destroyed. The average 6 granulocyte residence time is 10 days and is replaced at a rate of 10 h. The hallmark of an infective process is enhanced vascular permeability, leading to the leakage of fluid and small molecules at the affected site and associated transudation or diapedesis of leukocytes leading to local accumulation of these cells. The process of migration of granulocytes from the second compartment towards the sites of infection is considered to be an important factor for targeting foci of infection (3) . Radiopharmaceuticals utilize these properties to localize the lesion. It is for these reasons that the goal of developing an infection-specific imaging agent is a topic of much ongoing research. In this article
we will review the current progress of non-osseous infection imaging and discuss those agents that hold promise for further research and future clinical utility. with malignancy and in the postoperative period leading to low specificity (9) .
It is clear that as of now, an ideal infection imaging agent does not exist. Table 1 lists the current available strategies for developing these agents. The generally accepted characteristics that constitute an ideal imaging agent are listed below. The goal in development is to strive for an agent that comes as close as possible to meeting the following criteria:
• Accumulation only in those areas of active infection. Easily distinguishable from background uptake or low uptake in non-infected tissues.
• Absence of physiological accumulation of the tracer in the blood and bone marrow, liver, spleen and rapid washout of background activity.
• No adverse toxic effects and free of immune-reactions.
• Safe, quick, and cost-effective preparation.
• The ability of uptake at sites of infection in vivo, without requiring outside preparation and handling of blood products.
• Low radiation burden to the patient.
• Differentiation between infection and non-specific inflammation.
• Rapid blood clearance and rapid accumulation at the site of infection.
<<TABLE 1>>

Agents for Infection/Inflammation Imaging Currently in Clinical Use
Ga Citrate
Since 1971, 67 Ga citrate has been used to detect infection and inflammation.
Certain studies have suggested that following injection, the 67 Ga citrate forms a complex with transferrin, and undergoes extravasation at the site of inflammation/infection. The exact mechanism of retention in the infectious lesion is not entirely clarified, but data from various models support the role of bacterial siderophores and lactoferrin in leukocytes (10) .
Discrimination of infection is difficult using 67 Ga citrate due to the normal uptake that is found in the bowel, liver, spleen, bone and genitourinary system and its slow blood WBCs ranges from 86-90%, with a slightly higher sensitivity for acute infections likely due to the increased granulocytic response (12) . This discovery was a significant advancement over the traditional 67 Ga-citrate agent. Yet, WBCs are also able to localize to non-specific areas of inflammation and thus lack specificity for infection.
Nonetheless, ex vivo labeling of leukocytes to 18 F-FDG for 18 F-FDG -WBC hybrid PET/CT imaging was found to detect foci of infection with high precision.
Nonspecific Immunoglobulins
Nonspecific polyclonal human immunoglobulins have been shown to localize to sites of infection/inflammation by extravasation from the bloodstream due to the induced local hyperemia (13) Various in vitro studies of 18 F-FDG labeling of human leukocytes using mixed/ pure preparations of neutrophils and mononuclear cells have been reported. Granulocyte uptake accounted for 78%-87% of the activity in mixed preparations. Labeling of WBCs with 18 F-FDG was not stable and the labeling yield ranged from 40% to 80% when pure preparations of WBC were used. Neutrophils when stimulated for 60 min by N-formylmethionyl-leucyl-phenylalanine, a chemotactic peptide, revealed a significant increase in 18 F-FDG uptake (16) (17) (18) (19) .
In vivo labeling of WBCs using antibodies or antibody fragments
After the development of the above described techniques for labeling WBCs in vitro, the focus on discovery of an agent with the ability to label WBCs in vivo became an Tc were determined to allow the accurate delineation of infection and inflammation. It was reasoned that since neutrophils increase the expression of CD15 antigens when they become activated, these compounds should increase the amount of specific binding around sites of infection and, as a consequence, enhance the efficacy of the radiopharmaceutical as a diagnostic test (21) . None of these compounds, however, were specific for infection only as was original hypothesized.
After further investigation it appeared that the behavior of these antigranulocyte antibodies differed from that of radiolabeled WBCs. In short, it appears that they did not accumulate in the lungs post-injection and their circulatory clearance differed from that of their in vitro WBC labeled counterparts.
Mozley et al. later showed that a transient leukopenia typically occurred 15-20
min post-injection of the anti-CD15 antibody and recovered with a mild overcompensation in approximately one hour (21) . This transient leukopenia is not uncommon after injections of any compound and it has never been shown to be harmful or increase susceptibility to infections. Since that time, it has become widely accepted that the behavior of these MoAbs is largely due to a localized hyperemia and an increased 13 vascular permeability which is non-specifically associated with both infection and inflammation.
The future of radiolabeling WBCs using antibodies
The future of these compounds is uncertain due to the results of the few clinical trials that have been performed. Also there is the theoretic and real possibility of a HAMA to any antibody that is made of nonhumanized protein. Thus, the investigation of partial antibody fragments was undertaken to minimize these adverse reactions and to potentially avoid the transient pancytopenia that had been documented to occur with use of these agents (21) .
Respiratory Inflammation/Infection imaging
The literature and research surrounding respiratory infection imaging in nuclear medicine is relatively scarce. This is not to say that the imaging of this organ system does not hold promise and the studies to date have not been encouraging. As of now an important advance would be the development and general acceptance of an imaging modality that could quantitatively delineate lung inflammation, leading to the ability to monitor the therapeutic response in such diverse conditions as pneumonia, acute respiratory distress syndrome, cystic fibrosis, and Chronic Obstructive Pulmonary (27) . While PET seems promising for respiratory infection imaging, this study was performed on a unique patient population that made any focal lung uptake unlikely to be due to malignancy. Therefore, perhaps the clinical utility of FDG PET in diagnosing respiratory infections lies in certain specific sub-groups of patients where infection is suspected and malignancy highly unlikely.
The diagnosis of a pulmonary lesion seen on plain film or CT typically raises the question of infection (acute or chronic) which can be a difficult one to answer. However, the lack of clinical trials in respiratory infection imaging makes CT scanning and biopsy a necessity in a symptomatic patient in order to answer this question. With the increasing awareness of radiation dosages and discomfort associated with biopsy, it would be extremely beneficial to continue research in this area, especially with some of the newer, postulated infection-specific agents. This could negate biopsy or at the very least reduce patient anxiety and possibly decrease the necessity of high-resolution CT scanning.
Abdominal Inflammation/Infection Imaging
Inflammatory Disorders
The area of abdominal inflammation imaging centers on the imaging of Inflammatory Bowel Disease (IBD). IBD comes in two well described forms. The first, ulcerative colitis (UC) typically is limited to the colon, sparing the small bowel and anus.
Lesions are confined to the bowel mucosa, and they typically extend from a primary site rather than patches of inflammation. The other entity, Crohn's Disease (CD), can affect the entire length of the bowel, primarily displays skip lesions, and shows transmural inflammation on histopathology. More importantly, distinguishing the diagnosis between CD and UC is crucial, since therapeutic options differ greatly.
In the past, there were no general guidelines as to which of the many available tests was the best to use in a given clinical situation. (28) . Another specific indication is for determining recurrences on pre-anastomotic loops. In this case, WBC uptake can be classified semi-quantitatively comparing the activity to that of iliac crest, liver and or spleen (28) .
<<TABLE 2>>
Infectious Abdominal Disorders
Appendicitis is a very common disorder accounting for more than 1 out of 100 emergency room visits and affecting nearly all age groups. However, it has been shown that 30% of appendicitis presentations are misdiagnosed leading to the patient being discharged from the hospital with an erroneous diagnosis (29) . Moreover, the percentage of appendectomy where the appendix is normal is around 16%. This is particularly true for atypical clinical manifestations, or in certain populations, such as young children, pregnant women and elderly patients (28 TcMoAbs and can be indistinctly used (Table 3 ). All agents showed good sensitivity and specificity. However, this paper was published before the question arose as to certain complications resulting from the usage of these MoAbs, as these agents are no longer Tc-ciprofloxacin may be useful in the diagnosis of active spinal infections (38) .
However, the authors' also suggest that its usefulness in this particular area stems from this agents' ability to distinguish between bacterial and sterile inflammation. It should be noted that no controls were used in this study and since the time of publication it has been shown that 99m
Tc-ciprofloxacin is more likely a nonspecific indicator of inflammation than an infection specific agent.
In the inflammatory imaging spectrum of CNS imaging is the possibility of FDG PET usage to aid in diagnosing paraneoplastic neurological syndrome (PNS). In the patient with PNS, brain FDG PET and brain Magnetic Resonance Imaging (MRI) are both complementary to each other, and frequently, abnormalities noted on FDG PET images can provide additional information which is clinically significant (39) . In a review of four different published articles, the authors also found that in the setting of paraneoplastic cerebellar degeneration, FDG PET generally reveals cerebellar hypometabolism analogous to the cerebellar atrophy on MRI, but it also tends to show the abnormality more often than MRI (39) . These findings suggest that FDG PET may be a future tool for the initial workup of a patient with PNS having either a known or unknown malignancy.
Postoperative Infections
The diagnosis of a postoperative infection is often a difficult one to make A prospective multi-center study analyzing the value of FDG PET in 70 patients with FUO by Bleeker-Rovers and colleagues found that FDG PET contributed to determining the etiology in 30% of patients. Interestingly, they also found that FDG PET was not helpful in any patient with a normal erythrocyte sedimentation rate (ESR) and CRP. These findings suggest that FDG PET should be strongly considered as an early diagnostic study in patients presenting with FUO with an elevated ESR or CRP (43, 44) .
A more recent article from Bleeker-Rovers et al. nicely summarized the results of seven recent studies of FDG PET in patients with FUO (Table 4) . However, comparing one study to another is difficult due to the difference in study design, PET technique, time of imaging, and varying definitions of FUO (45, 46) .
FDG PET seems to be increasingly recognized as having utility in FUO and infection imaging as a whole. While the search for an infection-specific agent continues, in patients with FUO, 18 F-FDG can provide useful benefits. Its ability to show areas of increased glucose utilization, allows for visualization of more than one etiology such as:
infection, inflammatory disorders, malignancy, etc.
<<TABLE 4>>
Immunocompromised Infection Imaging
FDG PET can be a useful tool for diagnosing and managing infections even in the setting of severe neutropenia or lymphopenia (27) . In addition to this, FDG PET uptake has also been shown to correlate with the degree of HIV infection and increasing viral load (47) . We have already discussed the uses of PET in distinguishing between CNS infection and malignancy in patients with AIDS. But in addition to this, there seems to be utility in all cases of inherited or acquired neutropenia. This study again noted a transient leukopenia (65% reduction) that occurred 30 minutes after injection (53, 54) .
Future Outlook
Overall, the area of infection imaging in nuclear medicine is one rich with ongoing research. While an infection specific imaging agent is still lacking, the 27 development of one would greatly advance our ability to detect, localize, and quantify respiratory, abdominal, CNS, and post-operative infections. It appears that the superior spatial resolution of PET combined with CT for better anatomic localization is gaining support as a more effective means of infection imaging, especially in those with FUO or nonfunctional immune systems. Therefore, the hybridization of an infection specific radiopharmaceutical, imaged via SPECT or PET and combined with CT will pave the way for greater reliability and clinical utilization of these technologies in the evaluation of difficult patients. 
